Strategic partnership Potential sales opportunity with ECO Animal Health Group for collaborative development and commercialization of vaccines targeting Toxoplasma gondii in sheep, leveraging Vaxinano’s adjuvant-free Stellar-NP platform to reach key global livestock markets.

Funding traction Recent funding and awards signals validate investor confidence and growth trajectory; leverage these milestones to engage potential customers and partners highlighting stability and ongoing R&D investments.

Clinical and research credibility Publication and conference activity, including the PLOS Neglected Tropical Diseases paper and Colloque I3M presentation, provide talking points for credibility when approaching academic institutions and biotech buyers seeking innovative vaccine platforms.

Global market potential Vaxinano targets infectious diseases across parasites, viruses, bacteria, and fungi with a fast-to-deploy vaccine platform, presenting cross-vertical opportunities for government health programs, veterinary applications, and human health initiatives in underserved markets.

Technology differentiator Stellar-NP adjuvant-free, stable vaccine platform positions Vaxinano as a unique supplier for customers seeking safer, longer-lasting vaccines with simpler supply chains; tailor outreach to procurement teams prioritizing safety, durability, and deployment speed.